These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 22137234)

  • 1. Severity score indexes for blistering diseases.
    Daniel BS; Hertl M; Werth VP; Eming R; Murrell DF
    Clin Dermatol; 2012; 30(1):108-13. PubMed ID: 22137234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimated cut-off values for pemphigus severity classification according to pemphigus disease area index (PDAI), autoimmune bullous skin disorder intensity score (ABSIS), and anti-desmoglein 1 autoantibodies.
    Mohebi F; Tavakolpour S; Teimourpour A; Toosi R; Mahmoudi H; Balighi K; Ghandi N; Ghiasi M; Nourmohammadpour P; Lajevardi V; Abedini R; Azizpour A; Nasimi M; Daneshpazhooh M
    BMC Dermatol; 2020 Oct; 20(1):13. PubMed ID: 33129291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemphigus disease activity measurements: pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score.
    Rahbar Z; Daneshpazhooh M; Mirshams-Shahshahani M; Esmaili N; Heidari K; Aghazadeh N; Hejazi P; Ghajarzadeh M; Chams-Davatchi C
    JAMA Dermatol; 2014 Mar; 150(3):266-72. PubMed ID: 24429657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Objective scoring systems for disease activity in autoimmune bullous disease.
    Sebaratnam DF; Murrell DF
    Dermatol Clin; 2011 Jul; 29(3):515-20, xi. PubMed ID: 21605820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus.
    Boulard C; Duvert Lehembre S; Picard-Dahan C; Kern JS; Zambruno G; Feliciani C; Marinovic B; Vabres P; Borradori L; Prost-Squarcioni C; Labeille B; Richard MA; Ingen-Housz-Oro S; Houivet E; Werth VP; Murrell DF; Hertl M; Benichou J; Joly P;
    Br J Dermatol; 2016 Jul; 175(1):142-9. PubMed ID: 26800395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ODSS vs. ABSIS and PDAI oral parts in pemphigus vulgaris: inter-rater reliability and testing times.
    Shamabadi A; Yazdinezhad S; Sadeghi Y; Moradi AR; Yazdchi A; Teymourpour A; Faramarzi A; Seirafi R; Balighi K; Mahmoudi H; Daneshpazhooh M
    Oral Dis; 2023 Oct; 29(7):2696-2704. PubMed ID: 35852132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome measures for autoimmune blistering diseases.
    Zhao CY; Murrell DF
    J Dermatol; 2015 Jan; 42(1):31-6. PubMed ID: 25558950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reliability and convergent validity of two outcome instruments for pemphigus.
    Rosenbach M; Murrell DF; Bystryn JC; Dulay S; Dick S; Fakharzadeh S; Hall R; Korman NJ; Lin J; Okawa J; Pandya AG; Payne AS; Rose M; Rubenstein D; Woodley D; Vittorio C; Werth BB; Williams EA; Taylor L; Troxel AB; Werth VP
    J Invest Dermatol; 2009 Oct; 129(10):2404-10. PubMed ID: 19357707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond the skin: disease parameters in pemphigus.
    Viti G; Forcella C; Feliciani C; Murrell DF
    Ital J Dermatol Venerol; 2021 Apr; 156(2):147-150. PubMed ID: 33960750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the Correlation Between Disease Severity Indices and Quality of Life Measurement Tools in Pemphigus.
    Krain RL; Kushner CJ; Tarazi M; Gaffney RG; Yeguez AC; Zamalin DE; Pearson DR; Feng R; Payne AS; Werth VP
    Front Immunol; 2019; 10():2571. PubMed ID: 31781098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bullous autoimmune dermatoses. 1: Classification].
    Hertl M; Schuler G
    Hautarzt; 2002 Mar; 53(3):207-19; quiz 220-1. PubMed ID: 11974595
    [No Abstract]   [Full Text] [Related]  

  • 12. Classification and Antigen Molecules of Autoimmune Bullous Diseases.
    Hashimoto T; Qian H; Ishii N; Nakama T; Tateishi C; Tsuruta D; Li X
    Biomolecules; 2023 Apr; 13(4):. PubMed ID: 37189450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme-linked immunosorbent assay in autoimmune blistering diseases: preliminary experience of the Dermatology Department of Cagliari.
    Atzori L; Deidda S; Aste N
    G Ital Dermatol Venereol; 2008 Feb; 143(1):1-8. PubMed ID: 18833046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Oral Disease Severity Score validated for use in oral pemphigus vulgaris.
    Ormond M; McParland H; Donaldson ANA; Andiappan M; Cook RJ; Escudier M; Hullah E; Higham J; McMillan R; Taylor J; Shirlaw PJ; Challacombe SJ; Setterfield JF
    Br J Dermatol; 2018 Oct; 179(4):872-881. PubMed ID: 29297927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of an Excel® spreadsheet to document disease activity in autoimmune bullous disease.
    Sebaratnam DF; Venugopa SS; Murrell DF
    Acta Dermatovenerol Croat; 2013; 21(3):207-8. PubMed ID: 24183229
    [No Abstract]   [Full Text] [Related]  

  • 16. Validation of an Oral Disease Severity Score (ODSS) tool for use in oral mucous membrane pemphigoid.
    Ormond M; McParland H; Thakrar P; Donaldson ANA; Andiappan M; Cook RJ; Escudier ME; Higham J; Hullah E; McMillan R; Taylor J; Shirlaw PJ; Challacombe SJ; Setterfield JF
    Br J Dermatol; 2020 Jul; 183(1):78-85. PubMed ID: 31571192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Large International Validation of ABSIS and PDAI Pemphigus Severity Scores.
    Hébert V; Boulard C; Houivet E; Duvert Lehembre S; Borradori L; Della Torre R; Feliciani C; Fania L; Zambruno G; Camaioni DB; Didona B; Marinovic B; Schmidt E; Schumacher N; Hünefeld C; Schanz S; Kern JS; Hofmann S; Bouyeure AC; Picard-Dahan C; Prost-Squarcioni C; Caux F; Alexandre M; Ingen-Housz-Oro S; Bagot M; Tancrede-Bohin E; Bouaziz JD; Franck N; Vabres P; Labeille B; Richard MA; Delaporte E; Dupuy A; D'Incan M; Quereux G; Skowro F; Paul C; Livideanu CB; Beylot-Barry M; Doutre MS; Avenel-Audran M; Bedane C; Bernard P; Machet L; Maillard H; Jullien D; Debarbieux S; Sassolas B; Misery L; Abasq C; Dereure O; Lagoutte P; Ferranti V; Werth VP; Murrell DF; Hertl M; Benichou J; Joly P; ;
    J Invest Dermatol; 2019 Jan; 139(1):31-37. PubMed ID: 30301637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of autoimmune blistering diseases: the Pemphigoid diseases.
    Daniel BS; Murrell DF
    J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1685-1694. PubMed ID: 31087464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Ear, Nose, and Throat Involvement in Pemphigus Vulgaris in Comparison with Pemphigus Severity Scoring Systems: A Cross-sectional Study.
    Bilgic-Teme A; Cem Temel I; Bostancı-Toptas A; Turhan M; Bozkurt S; Uzun S
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):283-288. PubMed ID: 30665476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of anti-desmoglein-1 and -3 circulating autoantibodies in Pemphigus Patients Measured by Area Index and Intensity Score.
    Patsatsi A; Kyriakou A; Giannakou A; Pavlitou-Tsiontsi A; Lambropoulos A; Sotiriadis D
    Acta Derm Venereol; 2014 Mar; 94(2):203-6. PubMed ID: 23995461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.